Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK
- 14 August 2002
- journal article
- research article
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 24 (4), 263-265
- https://doi.org/10.1046/j.1365-2257.2002.00445.x
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Polymorphism in glutathione S -transferase P1 is associated with susceptibility to chemotherapy-induced leukemiaProceedings of the National Academy of Sciences of the United States of America, 2001
- Karyotype and age in acute myeloid leukemia.: Are they linked?Cancer Genetics and Cytogenetics, 2001
- Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adultsBlood, 2001
- A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trialBritish Journal of Haematology, 1999
- The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 TrialBlood, 1998
- The PACE (population-adjusted clinical epidemiology) strategy: a new approach to multi-centred clinical researchQJM: An International Journal of Medicine, 1997